Telomir Pharmaceuticals (NASDAQ: TELO) has announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1 (Zn-Telomir). The studies reported no treatment-related adverse or dose-limiting toxicities across cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models.
The preclinical-stage biotechnology company stated that Telomir-1 was well tolerated with no concerning cardiac or respiratory safety signals, no phototoxic potential, and only limited, reversible, and non-adverse findings in repeated-dose studies. The candidate also demonstrated consistent systemic exposure and predictable pharmacokinetics following oral administration, supporting continued advancement toward first-in-human clinical development pending completion of final quality assurance review and applicable regulatory pathways.
These findings are significant because they address a critical hurdle in drug development: ensuring safety before moving to human trials. The absence of dose-limiting toxicities suggests Telomir-1 has a favorable safety profile, which is essential for regulatory approval and eventual patient use. The predictable pharmacokinetics further enhance its potential as a viable therapeutic option.
For more details, the full press release is available at https://ibn.fm/Gaxtl.
Telomir Pharmaceuticals is a preclinical biotechnology company developing small-molecule therapeutics designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative disease. Its lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function.
The positive safety data mark a crucial step forward for Telomir Pharmaceuticals, bringing them closer to human clinical trials. Investors and stakeholders will be watching closely as the company progresses toward regulatory submissions and potential first-in-human studies.
For the latest news and updates relating to TELO, visit the company’s newsroom at https://ibn.fm/TELO.
